Risks and Warnings Both drugs carry warnings for: Possible thyroid C-cell tumors Pancreatitis Kidney damage in rare cases (due to dehydration from nausea) Neither is recommended for people with a personal or family history of medullary thyroid carcinoma
Research has pharmacokinetically validated Semaglutides approximately one-week half-life , documenting C18 fatty diacid-albumin binding kinetics, the albumin-dissociation equilibrium governing free versus bound Semaglutide fractions, renal clearance resistance, DPP-IV resistance of the Aib8 substitution, and the resulting sustained plasma exposure profile enabling once-weekly pharmacokinetics
Last reviewed: June 11, 2026 Last updated: June 11, 2026 Written by: Jay Hastings, CEO of PlexusDx Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations
Elevated liver enzymes
JULIE: My husband's starting Ozempic next week